**Major Items:**
Changfeng Pharmaceutical (02652) IPO scheduled from September 26 to October 2, plans global offering of 41.198 million H shares
Beijing Tongrentang (03613) received Traditional Medicine Registration License
Kanzhun Pharmaceutical (00867): Innovative drug ruxolitinib phosphate cream for AD indication achieved positive results in Phase III clinical trials in China
PulmonX Medical-B (09996): First patient treated in multi-center registration clinical trial of ReachTactile™ robot-assisted TAVR system
MINISO (09896) proposes spinoff of TOP TOY for independent listing on Hong Kong Stock Exchange main board
FOSUN PHARMA (02196) subsidiary Fosun Pharma Industry plans to participate in establishing private equity investment fund and considers transferring 100% equity of Shanghai Clone
BAIYUNSHAN PH (00874): Guangyao Phase II Fund plans to acquire 11.04% stake in Nanjing Pharmaceutical for RMB 748.8 million
ZMJ (00564) plans to invest in construction of new energy vehicle parts industrial base and R&D center project
Hisense Home Appliances (00921) plans to acquire 26.0006% equity interest in Hisense (Guangdong) Kitchen & Bath Systems for RMB 94.2905 million
New Energy Nexus (01799) subsidiary plans to acquire 100% equity of Xuyi Gaochuan for RMB 136.8 million
YUEXIU PROPERTY (00123) subsidiary plans to acquire 50.5% equity of Hangzhou Binde Real Estate Development Co., Ltd.
**Operating Performance:**
CHINA POWER (02380) combined total electricity sales in August approximately 11.7215 million MWh, up 4.78% year-on-year
Affluent Living Services (00331) released annual results with shareholders' attributable profit of HK$453 million, down 9.6% year-on-year
Asia Pacific Resources (01104) released annual results with shareholders' attributable profit of HK$244 million, down 37.48% year-on-year
Dali Group (00029) released annual results with shareholders' attributable loss of HK$62.594 million, turned from profit to loss year-on-year
Comments